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www.embomolmed.org EMBORecent advances in our understanding of the molecular pathways that govern the
association of inflammation with organ fibrosis and cancer point to the epithelial tosenchymal transition (EMT) as the common link in the progression of these
vastating diseases. The EMT is a crucial process in the development of different
sues in the embryo and its reactivation in the adult may be regarded as a
ysiological attempt to control inflammatory responses and to ‘heal’ damaged
sue. However, in pathological contexts such as in tumours or during the devel-
ment of organ fibrosis, this healing response adopts a sinister nature, steering
se diseases towards metastasis and organ failure. Importantly, the chronic
ammatory microenvironment common to fibrotic and cancer cells emerges as
ecisive factor in the induction of the pathological EMT.Introduction—EMT in cancer
and fibrosis
Although inflammation has been asso-
ciated with the progression of chronic
kidney disease and cancer for decades,
the molecular mechanisms involvedhave remained elusive until recently (Cordon-Cardo & Prives,
1999; Kalluri & Neilson, 2003; Mantovani et al, 2008). The
epithelial to mesenchymal transition (EMT) now takes centre
stage as the convergence point between inflammation and the
progression of degenerative fibrotic diseases and cancer. This
cellular process is characterized by the loss in cell polarity and a
change in cell shape from cuboidal to fibroblastoid, the
downregulation of epithelial markers and the upregulation of
mesenchymal markers. The cell acquires the capacity to degrade
the basement membrane and migrate through the extracellular
matrix to populate different territories either during embryonic
development or cancer progression, or to adopt a profibrotic
myofibroblast nature in the renal interstitial space (Acloque et
al, 2009; Kalluri & Neilson, 2003; Kalluri & Weinberg, 2009).
Betty Hay was the first to coin the term ‘epithelial to
mesenchymal transformation’ in embryos (Hay, 1968), as well
as later describing this cellular behaviour during migration
(Hay, 1990) and the importance of the transient nature of thissidad de Salamanca,
o, Salamanca, Spain.
Alicante, Spain.
(þ34) 965 919561;
Mol Med 1, 303–314process (Hay, 1991; Fig 1A). Ironically, important elements in
the control of the inflammatory response and in the induction of
tumour cell death such as TGF-b1 and hypoxia can also act as
potent inducers of EMT in an inflammatory microenvironment.
EMT events have been very well defined during embryonic
development for many years (reviewed in Acloque et al, 2009).
However, the significance of the EMT in cancer progression has
been debated until recently. The main discussion regarding the
role of EMT in cancer came from the difficulty in finding
morphological evidence from clinical samples, due to the lack of
specific markers for many years and the sometimes focal nature
of the event. Nevertheless, more than 100 years ago, both
Santiago Ramo´n y Cajal and Hugo Apolant noticed what we
would definitely consider an EMT in both human and mouse
breast cancer (Fig 1B,C). Indeed, the description of the breast
tumours by Cajal in his ‘Manual of Anatomopathology’ is
premonitory of the implication of the EMT as the first step in the
metastatic cascade. He referred to undifferentiated breast
carcinomas as follows: ‘The epithelial islands are not
surrounded by a basement membrane. . . We shall mention
the fusiform, pear-like and star-like forms. . . The cells are not
attached to each other. . . This explains their invasive ability,
since free of intercellular cement, they can migrate through the
connective tissue’ (Ramon y Cajal, 1890). When we read 2009 EMBO Molecular Medicine 303
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304‘cement’ in Cajal’s words we immediately think of E-cadherin,
the molecule that maintains epithelial cells together and that we
now know is the main target repressed by the EMT inducers.
Figure 1B and C shows fragments of Cajal’s and Apolant’s
drawings illustrating human and mouse breast carcinomas. The
reversibility of the EMT process has been well described in the
context of embryonic development, where mesenchymal to
epithelial processes (MET) are fundamental for the differentia-
tion of tissues and organs once the embryonic migratory cells
have reached their destination. Indeed, theMET events certainly
take place during metastasis formation as suggested by cell
morphology and the re-expression of E-cadherin expression
(Bukholm et al, 2000). This EMT–MET double switch for
metastasis formation has been discussed by Brabletz et al (2001)
while providing a convincing illustration of an EMT process at
the invasive front of human colon carcinoma (Fig 2A).
Fibrosis is characterized by the presence of an excess of
fibrous connective tissue in an organ, and in particular by an
excessive deposition of collagen I. It can be the result of a
reparative or reactive process that can occur in the lung, the
liver, the heart and the kidney among other organs. Under
chronic pathological situations, fibrosis progresses to advanced
states that lead to defective organ function and final organGlossary
Acute phase proteins
Proteins whose plasma concentrations increase (positive acute phase
proteins) or decrease (negative acute phase proteins) in response to
inflammation.
Angiogenesis
Development of blood vessels in the embryo or in an adult tissue.
Apoptosis
Cell death characterized by shrinkage of the cell, condensation of
chromatin and fragmentation of the cell into membrane-covered
bodies that are eliminated by phagocytosis.
Calculi
Abnormal mineral deposit.
Cytokines
Intercellular protein mediators released by immune cells to regulate
the immune response.
EMT or the epithelial to mesenchymal transition
The conversion of an epithelial to a mesenchymal cell during
embryonic development or in several pathologies.
Fibrosis
Development of excessive fibrous connective tissue in an organ.
Hypoxia
Exposure of the tissues to oxygen concentrations lower than normal;
Deficiency in the amount of oxygen reaching body tissues.
Inflammation
A poorly specific immune response of body tissues to infection,
irritation or other injuries, characterized by pain, swelling, redness
and heat.
Interstitial fibrosis
Accumulation of excessive fibrous connective tissue between the
parenchymal cells of an organ.
 2009 EMBO Molecular Medicinefailure. In this review we will focus on renal fibrosis as it has
been very well studied at the cellular level and the mechanisms
leading to the development of fibrosis are thought to be very
similar in different organs. Renal fibrosis is the link between the
progressive loss of renal function and primary diseases such as
glomerulonephritis, diabetes, toxic injury, congenital abnormal-
ities, urinary tract obstruction and chronic rejection of trans-
planted kidneys (Kalluri & Neilson, 2003; Liu, 2006; Vongwiwa-
tana et al, 2005). Renal fibrosis has been associated with the
activation of interstitial fibroblasts to give rise to collagen
secreting myofibroblasts. However, different studies have shown
that in addition, myofibroblasts can also originate from renal
tubular epithelial and endothelial cells that undergo EMT in
mouse models of renal fibrosis (Iwano et al, 2002; Zeisberg et al,
2008). Furthermore, the aberrant activation of Snail1, a well-
known EMT inducer leads to the appearance of renal fibrosis and
renal failure in transgenic mice (Boutet et al, 2006). Interestingly,
high Snail1 expression and evidence of EMT has also been found
in the kidneys of patients with renal fibrosis (Boutet et al, 2006;
Jinde et al, 2001; Rastaldi et al, 2002).
In this review, we will discuss the dual role of TGF-b1 and
hypoxia in fibrotic tissues and in the tumour microenvironment.
We propose that in the context of a chronic inflammatoryLeukocyte infiltration
Accumulation of blood cells in a tissue or organ.
Lymphocytes
Nearly colourless white blood cells found in the blood, lymph and
lymphoid tissues, involved in humoral and cellular immunity.
Macrophages
Large phagocytes developed from circulating monocytes that migrate
to tissues to eliminate cellular debris and particulate antigens. They
produce and respond to inflammatory cytokines.
Metastasis
The spreading of cancer from one part of the body to another.
Oxidative stress
Pathologic changes seen in living organisms in response to excessive
levels of cytotoxic oxidants and oxygen free radicals.
Phagocytes
Cells with the ability of engulfing and absorbing waste material, cell
debris, microorganisms or other foreign bodies in the bloodstream
and tissues.
Renin–angiotensin system
Endocrine system initiated by the release of the enzyme renin, which
acting on the circulating protein angiotensinogen produces the
decapeptide Ang I, which is transformed to the active hormone, the
octapetide Ang II.
Stromal cells
Cells found in the loose connective tissue which make up the support
structure of the organs and support the parenchymal cells (functional
elements of an organ).
Unilateral ureteral obstruction (UUO)
Acute obstruction of one of the ureters, mimicking the different stages
of ON and leading to tubulointerstitial fibrosis.
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Figure 1. The history of EMT in cancer.
A. Betty Hay coined the term ‘epithelial to
mesenchymal transformation’ (Hay, 1968) and
described the transient nature of this process, as
well as the reversion to the epithelial character
(MET, Hay, 1991). Modified from Acloque et al
(2008).
B. More than 100 years ago Santiago Ramo´n y
Cajal drew and described the morphological
appearance of breast carcinoma so accurately
that we can find what we believe to be the first
description of EMT (see text). Drawings are
adapted from figs. 53 and 48 in Ramon y Cajal
(1890). Note the morphology of the cell
highlighted as ‘b’.
C. At the turn of the 20th century, Hugo Apolant
also clearly represented the morphology of
EMT-type mouse mammary tumours (Apolant,
1906). The micrograph shows the distribution of
cytokeratin 8/18 in both the
epithelial and spindle cell populations in a
mouse mammary tumour diagnosed as
EMT-type. This picture is courtesy of Dr P.
Damonte and Dr R. Cardiff, Univ. California at
Davis.condition, TGF-b1 and hypoxia reactivate EMT developmental
programmes that converge in the activation of NF-kB also
induced by the inflammatory cytokines and oxidative stress.
These EMT programmes, in an unsuccessful attempt to repair
the injured tissue, turn to a sinister role and lead to the
destruction of epithelial homeostasis and accumulation of
extracellular matrix in fibrosis, and to the progression of
carcinomas towards the metastatic state.Inflammation as an inducer of
fibrosis and cancer
Inflammation and cancer
The link between cancer and inflammation has been recognized
for decades, as strong associations have been established
between chronic inflammatory conditions and tumourigenesis
(Cordon-Cardo & Prives, 1999). As such, ulcerative colitis,
chronic gastritis, hepatitis and chronic pancreatitis, and their
respective relationships with colon, gastric, liver and pancreatic
carcinomas exemplify the close connection between inflamma-
tion and tumour appearance. Furthermore, non-steroidal anti-
inflammatory drugs reduce both the risk of cancer development
and its mortality (Mantovani et al, 2008).
Renal fibrosis as an inflammatory disease
Renal fibrosis is a paradigmatic example of organ fibrosis
towards degenerative organ disease and final stage kidney
damage leading to the destruction of the tissue and death fromwww.embomolmed.org EMBO Mol Med 1, 303–314renal failure. Obstructive nephropathy (ON) in humans, either
due to congenital or acquired obstruction of the urinary tract, is
the first primary cause of chronic renal failure (CRF) in children
and amajor cause of kidney failure in adults (Klahr &Morrissey,
2002; Smith et al, 2007). In ON, the evolution of renal disease is
similar to that occurring in polycystic kidney disease or renal
transplant rejection. Moreover, in its final fibrotic phase, ON is
also very similar to the fibrosis secondary to glomerulonephritis,
diabetes or hypertension (Chevalier, 2006; Chevalier et al,
2009). Indeed, long-term ON is characterized by tubular atrophy
and the appearance of fibrosis (Fig 2B). Studies of ON have
benefited from the existence of a recognized experimental
model, the unilateral ureteral obstruction (UUO), in mice. UUO
does not compromise the life of the animal, as the contralateral
kidney maintains or even augments its function offering
functional compensation (Klahr & Morrissey, 2002). Since
UUO reproduces all the hallmarks of ON and it generates
progressive renal fibrosis, it has become the standard experi-
mental model to study the causes and mechanisms underlying
tubulointerstitial fibrosis (Chevalier et al, 2009). Even though
ON is not an immune disease, it has a major inflammatory
component, characterized by the overexpression of inflamma-
tory genes, the release of pro-inflammatory cytokines, the
activation of NF-kB and the infiltration of macrophages and
lymphocytes (Diamond, 1995; Esteban et al, 2004; Misseri et al,
2005; Silverstein et al, 2003). Similarly, fibrosis can also be
considered as the end result of chronic inflammatory reactions
induced by a variety of stimuli including persistent infections,
autoimmune reactions, allergic responses, chemical insults, 2009 EMBO Molecular Medicine 305
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Figure 2. Histological features of EMT in cancer and fibrosis.
A. Immunohistochemical staining of a colorectal carcinoma for b-catenin in
red and nuclear counterstaining in blue. The central area of the tumour
exhibits polarized epithelial tumour cells lacking nuclear b-catenin, while
cells at the invasive front undergo EMT and show nuclear b-catenin
(Brabletz et al, 2001). Picture from Dr Thomas Brabletz, Univ. Freiburg
(Germany).
B. Histological sections showing the halmarks of EMT in the medulla of
fibrotic kidney from patients subjected to nephrectomy. Sections are
stained with haematoxylin–eosin (H/E) to better appreciate cell
morphology and the disappearance of the tubular structures in fibrosis,
vimentin expression showing mesenchymal cells (brown, Vim) and fibrotic
deposits revealed by the blue Masson–Trichome staining (M/T) (Boutet
et al, 2006).
306radiation, tissue injury and normal ageing (Kalluri & Neilson,
2003). Therefore, ON and UUO can be used as a reference for the
development of fibrosis, in part because inflammatory
responses have been analysed in depth in this model.NF-kB activation in fibrosis and cancer
After renal obstruction, an increase in the expression of the
prototypical pro-inflammatory cytokines tumour necrosis factor
(TNF-a) and interleukin-1 (IL-1) is crucial for the induction of
NF-kB, the major inflammatory response pathway, and for
recruitment of inflammatory cells to the obstructed kidney
(Meldrum et al, 2006; Metcalfe et al, 2008; Misseri et al, 2005;
Silverstein et al, 2003; Yamagishi et al, 2001). An increase in
leukocyte infiltration, especially macrophages and T lympho-
cytes, is detected as early as 4–12 h after ureteral obstruction,
and it continues to increase over the following days (Diamond,
1995). These cells play a central role in the renal inflammatory
response to UUO as the progression of renal injury is closely 2009 EMBO Molecular Medicineassociated with their accumulation and blocking their recruit-
ment protects against interstitial fibrosis (Lange-Sperandio et al,
2007). The recruitment of circulatory leukocytes is mediated by
several mechanisms including the expression of pro-inflamma-
tory, profibrotic and chemoattractant cytokines in the kidney
and the corresponding leukocyte chemotactic response to those
chemokines (Ferenbach et al, 2007).
Once activated, NF-kB generates a loop that maintains
the inflammatory signals as it controls the expression of
genes encoding pro-inflammatory cytokines (e.g. IL-1, IL2, IL-6,
TNF-a, etc.), chemokines (e.g. IL-8, MIP-1 a, MCP-1, RANTES,
eotaxin, etc.), adhesion molecules (e.g. ICAM, VCAM,
E-selectin), inducible enzymes (COX-2 and iNOS), growth
factors, some of the acute phase proteins and immune receptors,
all of which play critical roles in controlling most inflammatory
processes (Blackwell & Christman, 1997; Fig 3). As inflamma-
tion plays an important role in fibrosis, inhibition of NF-kB has a
big impact on the development of chronic kidney disease.
Indeed, NF-kB inactivation prevents inflammatory injury and
diminishes the expression of inflammatory genes after UUO
(Esteban et al, 2004; Miyajima et al, 2003). Similarly, increasing
the levels of the endogenous inhibitor of NF-kB, I-kB, or
inhibiting the pathway by the administration of curcumin,
reduces renal fibrosis and macrophage influx following UUO or
protects against interstitial inflammation in ON, respectively
(Kuwabara et al, 2006; Tashiro et al, 2003).
Like the injured kidney, inflammation or infection in the
context of a neoplasia can trigger the activation of NF-kB, the
main transducer of inflammatory responses, which in turn
induces the secretion of a plethora of inflammatory cytokines
(Fig 3). These cytokines recruit inflammatory cells and, at the
tumour–stroma interface, tumour cells together with tumour-
associated macrophages (TAMs) and cancer-associated fibro-
blasts (CAFs) again converge in producing NF-kB and the
hypoxia-inducible factor (HIF1-a), generating a microenviron-
ment capable of driving tumour progression (Mantovani et al,
2008). HIF-1 is a potent inducer of EMT in the kidney and also in
cancer cells in general (see Box 1 and Fig 3) and the
inflammation-mediated increase in NF-kB expression has been
associated with several aspects of cancer development, mainly
resistance to apoptosis and increased angiogenesis, with some
connections to invasiveness (Karin, 2006).
NF-kB can also directly activate the expression of potent EMT
inducers, including Snail1 and Zeb factors (Bachelder et al,
2005; Barbera` et al, 2004; Chua et al, 2007; Julien et al, 2007;
Kim et al, 2007) (Fig 3). Thus, there seems to be an important
connection between cancer, inflammation and EMT. This
connection has been reinforced recently by the finding that
TNF-a induces Snail1 promoter activity and EMT in cancer cells
(Dong et al, 2007) and that it can also stabilize Snail1 protein
(Wu et al, 2009). Snail1 is a highly unstable protein, targeted for
degradation by phosporylation and ubiquitylation mediated by
GSK-3b and SCFb-Trcp, respectively (Zhou et al, 2004). TNF-a
induces Snail1 protein stabilization by activating the expression
of the COP9 signalosome 2 (CNS2), which in turn inhibits the
binding of Snail1 to GSK-3b and b-Trcp (Wu et al, 2009; Fig 3).EMBO Mol Med 1, 303–314 www.embomolmed.org
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Figure 3. Inflammation, oxidative stress and
hypoxia cooperate in the induction of EMT for the
progression of organ fibrosis and cancer
metastasis. In the fibrotic kidney or in the tumour
inflammatory microenvironment TNF-a, Ang II,
reactive oxygen species (ROS) and hypoxia converge
in the induction of NF-kB, the main inflammatory
response pathway. TGF-b is first secreted to control
the inflammatory response (dotted red line) but in a
chronic inflammatory environment it behaves as a
fibrogenic agent and as an inducer of invasiveness.
Indeed, the signals released in response to
inflammation, oxidative stress ad hypoxia in the
stromal or interstitial cells (TAMs, CAFs, leukocytes
and myofibroblasts) induce the EMT process in
renal and carcinoma cells. TGF-b, NF-kB and
hypoxia play a crucial role in the activation of EMT
inducers in renal or carcinoma cells. NF-kB and
hypoxia also contribute to the EMT process
increasing the stability of the inducers. CAFs, cancer
associated fibroblasts; CNS2, component of the
signalosome; HIF1-a, hypoxia factor 1a; LOX,
lysyl-oxidase; TAMs, tumour-associated
macrophages.Interestingly, both transcriptional and post-transcriptional
mechanisms act through the induction of the main target of
TNF-a in the inflammatory response, NF-kB.
The link between TNF-a and Snail factors points to the EMT as
the molecular and cellular explanation for the association
between inflammation, fibrosis and tumour progression. As
mentioned above, EMT events are now directly associated with
invasion and metastasis in cancer progression. Elegant in vivo
imaging studies have shown that carcinoma cells migrate from
mouse primary tumours through a process of EMT and that this
process is dependent on an inflammatory microenvironment
provided by the TAMs and other stromal cells such as the CAFs
(Condeelis & Segall, 2003) (Fig 3). TAMs and stromal cells in
general are essential for angiogenesis, extracellular matrix
remodelling and the inflammatory response associated with
cancer (Condeelis & Pollard, 2006). Stromal cells secrete TNF-awww.embomolmed.org EMBO Mol Med 1, 303–314which, as in renal cells in the obstructed kidney, inducesNF-kB in
the tumour cells. The significance of NF-kB activation in cancer
cells is evident from the results obtained in inflammation-
associatedmodels of cancer (Karin & Greten, 2005; Pikarsky et al,
2004). Selective inactivation of NF-kB in these tumours led to
deficient tumour development. Importantly, at least in the liver,
activation of NF-kB was not important in the early stages of
tumour development, but was crucial for malignant conversion
and for the survival of tumour cells. This combined effect is very
reminiscent of that produced by the EMT inducers and Snail in
particular as, in addition of triggering EMT, Snail-expressing cells
are resistant to the cell death induced by the removal of survival
factors, by genotoxic stress, chemotherapy and immunotherapy
and even by TNF-a (reviewed in Barrallo-Gimeno & Nieto, 2005;
see also Kudo-Saito et al, 2009; Vega et al, 2004). In addition to the
activation of Snail1 by NF-kB, it should be noted that angiotensin 2009 EMBO Molecular Medicine 307
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Box 1: The dual role of hypoxia in fibrosis and
cancer
As TGF-b1, hypoxia has an early beneficial role in fibrosis and cancer, but
as if both were Dr Jekyll and Mr Hyde they can take a sinister role
that favours the progression of the disease (Bottaro & Liotta, 2003;
Massague, 2008). Indeed, TGF-b1 can act as a tumour suppressor or as a
promoter of invasion and metastasis, and in the injured kidney, it
can behave either as a healing anti-inflammatory cytokine or as a
profibrotic agent (see main text). Similarly, while cutting off the oxygen
supply seemed a good strategy to kill cancer cells since they massively die
at low oxygen concentrations, hypoxia increases the aggressiveness in
tumours and promotes renal fibrosis. Interestingly, they share a common
mechanism to fulfil their deleterious role, the induction of the EMT.
Hypoxia is an important factor in the development of tissue fibrosis.
The obstructed kidney suffers from chronic hypoxia due to a reduced
renal blood flow (Hegarty et al, 2001). Hypoxia regulates the expression
of a variety of growth factors and cytokines through the activation of the
HIF-1a, a potent transcriptional regulator of oxygen-dependent genes,
including VEGF and TGF-b1 (Baan et al, 2003) (Fig 3). In accordance with
the induction of TGF-b1 by HIF-1a, hypoxia also enhances EMT in vitro,
and genetic ablation of epithelial HIF-1a in a mouse model of renal
fibrosis was associated with reduced ECM accumulation. Interestingly, in
addition to inducing TGF-b1, HIF-1a can also directly activate the
expression of EMT inducers Snail, Twist and the members of the Zeb
family (Evans et al, 2007; Krishnamachary et al, 2006; Sun et al, 2009;
Yang et al, 2008) (Fig 3). This activation can occur in renal cells subjected
to hypoxia or that constitutively express HIF-1a, as found in those
defective in the von Hippel–Lindau (VHL) tumour suppressor. Further-
more, hypoxia also enhances Snail1 activity by activating the expression
of its partners lysyl-oxidases (LOX) both in the kidney after UUO and in
cancer cells, thereby promoting fibrogenesis and tumour progression
through the reinforcement of the EMT programme (Higgins et al, 2007;
Sahlgren et al, 2008) (Fig 3). Importantly, there is a reciprocal activation
of HIF-1a and NF-kB (Rius et al, 2008), reinforcing the EMT programme
(Fig 3). Thus, rather than dying, many cells in tumours and in the
damaged kidney can benefit from a lack of oxygen through the induction
of EMT, favouring the progression of cancer and fibrosis.
308II (Ang II), which behaves as a pro-inflammatory cytokine in the
kidney (see below) is able to induce oxidative stress in cancer
cells (Uemura et al, 2008), where there is an increase in the
production of reactive oxygen species (ROS) which, in turn, also
stimulates the transcription of Snail1 and favours EMT (Radisky
et al, 2005) (Fig 3). This is in agreement with the finding that Ang
II receptor inhibitors have beneficial effects on cancer progression
and metastasis (Dehayes & Nahmias, 2005). Needless to say,
hypoxia is also present inmany regions of the tumour, reinforcing
the activation of EMT inducers including Twist, Zeb and Snail
factors (see Box 1 and Fig 3).
Back to the kidney, renal obstruction leads to the activation of
the intrarenal renin–angiotensin system (RAS) and Ang II
(Chevalier, 2006; Ruiz-Ortega et al, 2003) (Fig 3), thus promoting
inflammation. Following UUO, and acting as a pro-inflammatory
cytokine, Ang II also activates NF-kB (Morrissey & Klahr, 1997),
which in turn stimulates the angiotensinogen gene (Klahr &
Morrissey, 2002). In addition to NF-kB, Ang II signalling through
its AT1 and AT2 receptors augments the expression of other pro-
inflammatory genes, including those encoding IL-6, monocyte
chemoattractant protein 1 and RANTES (Esteban et al, 2003;
Ruiz-Ortega et al, 2001; Wolf et al, 1997). Increased Ang II
production and the accumulation of activated phagocytes in the
interstitial space following UUO lead to an increase in oxidative
stress, concordant with the elevated levels of ROS in the
chronically obstructed kidney (Kawada et al, 1999; Moriyama et
al, 2001). Simultaneously, the activity of the anti-oxidant
enzymes catalase and copper-zinc superoxide dismutase, which
prevent free radical damage, is low in the obstructed kidney
(Ricardo et al, 1997). The resulting increase in oxidative stress
plays an important role in inducing an inflammatory state after
obstruction, as oxidative stress is a major activator of the NF-kB
pathway (Gloire et al, 2006; Fig 3). 2009 EMBO Molecular MedicineIn summary, while some steps of the pathways involved may
be tissue or disease specific, it is clear that in both cancer and
fibrosis the concerted action of several cytokines as IL-1b and
TNF-a plus Ang II together with oxidative stress and hypoxia
converge on the activation of NF-kB, a major inducer of the
inflammatory response.Yin and Yang of TGF-b1
In addition to the secretion of inflammatory cytokines, many
organs and tissues release TGF-b1 after an injury, as seen in the
lung, liver, heart, kidney and bone (Devescovi et al, 2008;
Frangogiannis, 2008; Kaneto et al, 1993; Kisseleva & Brenner,
2008; Gharaee-Kermani et al, 2009; Gressner et al, 2008).
TGF-b1 is considered a major anti-inflammatory cytokine, as
TGF-b1 knockout mice suffer from a lethal multifocal inflam-
matory disease (Kulkarni et al, 1993; Letterio & Roberts, 1998)
and the blockage of TGF-b1 signalling in T cells or in bone
marrow results in similar multifocal inflammatory responses
(Gorelik & Flavell, 2000; Shull et al, 1992). However, TGF-b1
has been known for many years to display a schizophrenic
behaviour in cancer. While it can act as a tumour suppressor at
early tumour stages, it can later contribute to the malignant
progression by promoting invasion and metastasis (Massague,
2008). In the kidney too, although TGF-b1 acts as an anti-
inflammatory cytokine to heal the injured kidney, it also has
negative effects on the development of chronic renal disease as it is
an important fibrogenic agent. Indeed, the role of TGF-b1 as a
promoter of tumour progression and profibrotic agent is associated
with its ability to act as a potent activator of EMT inducers (Acloque
et al, 2009). The Yin and Yang of TGF-b1 in both cases are explored
below.EMBO Mol Med 1, 303–314 www.embomolmed.org
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There are paradigmatic examples illustrating how TGF-b1 can
impair tumourigenesis while promoting metastasis (Siegel et al,
2003, reviewed inMassague, 2008). In normal cells, TGF-b1 can
maintain tissue homeostasis by suppressing cell proliferation
and by inducing apoptosis. Tumour cells evade this response by
losing the ability to respond to the cytostatic and apoptotic
effects through differentmechanisms (Shi &Massague, 2003). In
addition, TGF-b1 helps cancer cells to acquire the ability to
invade and disseminate by inducing the EMT process. Thus,
TGF-b1 is a potent EMT inducer in tumours albeit it is also
initially secreted to control pathological proliferation and
inflammation.
The study of the molecular pathways that drive the
differential response to TGF-b1 continues to be a very active
field of research and recent findings indicate that both genetic
and epigenetic mechanisms are involved. On one hand, the
methylation state of the platelet-derived growth factor (PDGF)
gene limits the proliferative or cytostatic effect of TGF-b1 in
gliomas (Bruna et al, 2007) and the concerted action of TGF-b1
with oncogenic Ras and mutant p53 sequester p63 in a complex
that inactivate its tumour suppressor effects (Adorno et al,
2009). This indicates that two molecules frequently mutated in
cancer, p53 and Ras, can divert the response to TGF-b1 towards
the promotion of metastasis. Indeed, TGF-b1 and oncogenic Ras
cooperate in the induction of Snail1 expression and EMT in
epithelial cells (Peinado et al, 2003). Interestingly, NF-kB is
required for the induction and maintenance of the EMT by TGF-
b1 in mammary epithelial cells overexpressing the Ras
oncogene (Huber et al, 2004), explaining the role of NF-kB as
a modulator of TGF-b1-induced EMT in addition to its role as a
direct activator of the EMT inducers.
Butwhat are the sources of TGF-b1 in the tumours? Again, as in
the injured organs, TGF-b1 is produced by cancer cells and,
particularly, by stromal cells in an attempt to control inflamma-
tion. TNF-a can induce TGF-b1 in lung fibroblasts (Sullivan et al,
2009) and TGF-b1 can also activate the resident fibroblasts to
convert them into myofibroblasts, called cancer-associated
fibroblasts in the contexts of tumours (CAFs) and associated
with tumour invasion (Micke & Ostman, 2005). Some of these
‘myofibroblastic’ CAFs are surely the result of the EMTundergone
by carcinoma cells, as EMT is now recognized as an important
event in carcinoma progression.
TGF-b1 in fibrosis: anti-inflammatory and healing factor
versus profibrotic factor
The release of TGF-b1 by renal or by infiltrating cells in the
damaged kidneymoderates the inflammatory reaction and helps
to heal the damaged tissue. Among its anti-inflammatory
functions, TGF-b1 antagonizes the pro-inflammatory cytokines
IL-1 and TNF-a in glomerular disease, and it is a prominent
macrophage deactivator during kidney injury (Kitamura & Suto,
1997). Renal TGF-b1 mRNA expression increases considerably
after the onset of obstruction (Kaneto et al, 1993), and its
concentration increases in the plasma of patients with
obstruction due to ureteral calculi and renal fibrosis (Liu,www.embomolmed.org EMBO Mol Med 1, 303–3142006; Vuruskan et al, 2005). TGF-b1 expression is induced by
Ang II (Wolf, 2006), upon increased stretch of tubular epithelial
cells (Quinlan et al, 2008), and it is also produced by interstitial
fibroblasts and infiltrating macrophages (Diamond et al, 1998;
Ding et al, 1993). As already mentioned, in addition to its anti-
inflammatory effects, TGF-b1 also acts as a profibrotic agent.
The profibrotic effect of TGF-b1 is achieved by increasing the
synthesis of matrix proteins and the expression of proteinase
inhibitors, including plasminogen activator inhibitor-1 (PAI-1),
and by decreasing that of ECM-degrading proteins such as
collagenase (Chevalier, 2006). Therefore, sustained aberrant
expression of TGF-b1 results in the pathological accumulation
of extracellular matrix material in both the glomerulus and
interstitial compartments (Bottinger, 2007). TGF-b1 also has
some pro-inflammatory properties, as it functions as a chemo-
attractant for leukocytes (Wahl et al, 1987) and induces COX-2
in mesangial cells (Rodrı´guez-Barbero et al, 2006). This
profibrotic activity of TGF-b1 reflects its behaviour as a
potent inducer of EMT, which contributes to the conversion
of renal epithelial cells into myofibroblasts in the context of the
injured kidney. In addition, part of the TGF-b1-induced
EMT programme promotes the remodelling of the cell contacts
with the basal membrane by activating the matrix metallopro-
teases MMP2 and MMP9 (Li et al, 2003; Strutz et al, 2002),
leading to the degradation of the collagen type IV component of
basement membrane. Thus, the molecule secreted to control
inflammation has an alter ego and it promotes the development
of fibrosis.
TGF-b1, myofibroblasts and EMT
Myofibroblasts play a major role in interstitial fibrosis as they
are the main source of matrix proteins. They originate from
several sources, including bone marrow cells, resident
interstitial fibroblasts, vascular pericytes, as well as endothe-
lial and tubular epithelial cells (reviewed in Grande & Lopez-
Novoa, 2009). As mentioned above, TGF-b1 contributes to the
formation of myofibroblasts through the activation of resident
fibroblasts and by inducing the transition to mesenchyme of
epithelial and endothelial cells via EMT or EndMT, respectively
(Zavadil & Bo¨ttinger, 2005; Zeisberg & Kalluri, 2008; Zeisberg
et al, 2008). Indeed, the transformation of tubular and
endothelial cells to mesenchymal cells contributes to more
than 60% of the myofibroblast population in the obstructed
kidney after UUO (Iwano et al, 2002; Zeisberg et al, 2008), and
this process plays a major role in tubulo-interstitial
fibrosis (Kalluri & Neilson 2003). The induction of EMT by
TGF-b1 also explains the fibrotic effect of Ang II, as this anti-
inflammatory factor also induces the synthesis of TGF-b1 and
its receptors in tubular epithelial cells (Wolf, 2006). Accord-
ingly, the infusion of Ang II into mice subjected to UUO
significantly increases their collagen content (Ma et al, 2003).
The induction of EMT by TGF-b1 in the renal cells takes
several days and requires the interplay of many pathways,
involving SMAD proteins (Li et al, 2002), the integrin-linked
kinase (Li et al, 2003) and Rho-family GTPases (Bhowmick et al,
2001;Masszi et al, 2003).b-Catenin is another key element in the
myofibroblast transition as it synergizes with TGF-b1 in 2009 EMBO Molecular Medicine 309
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310activating the a-smooth muscle actin (aSMA) gene and protein
expression (Masszi et al, 2004). The processes triggered by TGF-
b1 converge in the activation of the so-called EMT inducers,
which are transcription factors capable of eliciting this dramatic
phenotypic change that converts epithelial cells into activated
‘myofibroblast-like’ cells. As in cancer, among the transcription
factors involved in the induction of EMT, Snail factors have
been associated with renal fibrosis and significantly, TGF-b1 is
the most potent inducer of Snail transcription (Fig 3). The
expression of these genes increases in the obstructed kidney after
UUO (Sato et al, 2003; Tan et al, 2006; Yoshino et al, 2007) and
Snail1 activation is sufficient to induce EMT and all the hallmarks
of kidney fibrosis in adult mice (Boutet et al, 2006). Snail1 directly
represses E-cadherin transcription and that of the renal-specific
Cadherin16 gene through the direct repression of HNF-1b gene
expression. Snail also activates, albeit indirectly, the transcription
of mesenchymal genes, such as vimentin and aSMA, and it
promotes collagen I synthesis and deposition (Boutet et al, 2006).
Interestingly, Snail factors are strongly upregulated in fibrotic
kidneys from patients subjected to nephrectomy due to urinary
obstruction and kidney failure (Boutet et al, 2006). Altogether,
data frommany laboratories indicate that Snail factors are crucial
mediators of TGF-b1-induced EMT.Pending issues
The development of additional in vivo models to assess the full
significance of EMT in cancer and organ fibrosis.
The characterization of the full complement of EMT inducers
activated in organ fibrosis.
The development of optimized antibodies specific for the EMT
inducers that can work on histopatological sections.
The development of therapies directed towards the inhibition of the
EMT process.
The optimization of methods for the delivery of RNA interference
reagents.Concluding remarks and perspectives
From all the work carried out in the context of organ fibrosis and
cancer we can conclude that the pathways and players identified
that lead to pathological EMTs are basically the same. Both in
cancer and fibrosis TGF-b1, TNF-a and hypoxia cooperate in the
triggering of EMT, converging in the induction of Snail activity
through different mechanisms among which the activation of
NF-kB seems to play a central role. This can be regarded as the
reactivation of a developmental programme designed to endow
cells with migratory and invasive properties and with amazing
survival properties, crucial for migratory cells to reach their
sometimes far destinations within the embryo (Acloque et al,
2009). This developmental programme, firstly reactivated to
control the inflammatory response and to heal the injured tissue,
is corrupted in the context of chronic inflammation and cancer,
favouring the survival of injured or malignant cells and
stimulating the production of pro-inflammatory cytokines in
the tumour mass or in the organ interstitial space. The
cooperation between TGF-b1 and the pro-inflammatory cyto-
kines generates a microenvironment that favours the generation
of autoregulatory loops to reinforce the EMT programme (Fig 3).
Not only Ang II, TNF-a, ROS and hypoxia converge in the
induction of Snail, but also Ang II and TNF-a can induce TGF-b1
at the transcriptional level (Sullivan et al, 2009), the most potent
Snail inducer. In addition, Snail1 itself also seems to upregulate
the expression of pro-inflammatory mediators such as several
ILs (IL-1, IL-6, IL-8; Lyons et al, 2008). It will be interesting to
determine whether other EMT inducers are also activated in the
context of this inflammatorymicroenvironment, which seems to
be very likely, given that both TGF-b1 and hypoxia can induce
the expression of Twist and Zeb transcription factors. 2009 EMBO Molecular MedicineThe relationship between inflammation and Snail activity has
been established in cancer cells from different origins, indicating
that this is a general mechanism in carcinoma progression.
While themajority of studies on fibrosis have been carried out in
the kidney, the same pathways are likely to operate during other
fibrotic processes, including those in the liver and the lung,
especially since there is evidence of EMT in hepatic fibrosis (Kim
et al, 2006; Zeisberg et al, 2007a). A similar process also occurs
when endothelial cells undergo an EMT during cardiac or renal
fibrosis (EndMT; Zeisberg et al, 2007b, 2008) as well as during
mesothelial fibrosis in patients subjected to peritoneal dialysis
where the NF-kB/Snail1 axis has already been described
(Strippoli et al, 2008).
In summary, the relationship between inflammation and EMT
seems to be a conserved feature in the progression of organ
fibrotic diseases and cancer, suggesting that specific anti-EMT
drugs should be considered to treat these conditions in
combination with anti-inflammatory therapies. With respect to
therapies targeting the EMT programme, small molecule
inhibitors or antibodies directed against TGFbR have been
effective in preclinical and clinical trials, and neutralizing
antibodies against TGF-b1 are in Phase 1 clinical trials for renal
cell carcinoma and pulmonary fibrosis (Chua et al, 2008).
Treatment with BMP7, an inhibitor of TGF-b1 signalling, is a
promising strategy to treat fibrosis as it can reverse TGF-b1-
induced renal fibrosis in mice (Zeisberg et al, 2003). It should be
noted that since signalling molecules such as TGF-b1 or hypoxia
trigger complex transduction cascades with deleterious but also
beneficial outcomes, inhibiting the EMT inducers rather than the
extracellular signalling molecules or their receptors could provide
a more specific way to fight both fibrosis and cancer progression.
However, EMT inducers are transcription factors, and thus very
difficult to target. While RNA interference approaches are
promising specific reagents, these are still early days for their
wide use due to their low stability and, more importantly, due
to the current low efficiency in their cell targeting and intracellular
delivery. Finally, as the same signalling pathways can act as
promoters or suppressors of fibrosis and cancer, better under-
standing of the cellular response that depends on the context and
stage of the disease is crucial to design more advanced therapies.EMBO Mol Med 1, 303–314 www.embomolmed.org
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